Skip to content

Nuo Therapeutics, Inc.: 10-Q filed 2025-10-30

What Nuo Therapeutics, Inc. reported in its quarterly report filed 2025-10-30 (fiscal Q3 2025): 40 published measures, 108 facts as tagged in accession 0001437749-25-032437.

This filing

Form
10-Q (quarterly report)
Filed
2025-10-30
Fiscal period
fiscal Q3 2025
Accession
0001437749-25-032437 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Nuo Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-301,927,637USD
At 2024-12-311,189,508USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-302,347,243USD
At 2024-12-31675,796USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-30-419,606USD
At 2025-06-30-824,561USD
At 2025-03-31-213,073USD
At 2024-12-31513,712USD
At 2024-09-30890,387USD
At 2024-06-30598,513USD
At 2024-03-31333,448USD
At 2023-12-311,039,148USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-30514,797USD
At 2024-12-31283,714USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-537,919USD92
2025-01-01 to 2025-09-30-1,933,736USD273
2025-04-01 to 2025-06-30-649,689USD91
2025-01-01 to 2025-03-31-746,128USD90
2024-07-01 to 2024-09-30-578,167USD92
2024-01-01 to 2024-09-30-1,827,039USD274
2024-04-01 to 2024-06-30-540,091USD91
2024-01-01 to 2024-03-31-708,781USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-442,325USD273
2024-01-01 to 2024-09-30-1,741,083USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-01-01 to 2025-09-30231,551USD273
2024-01-01 to 2024-09-30154,962USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-30904,959USD273
2024-01-01 to 2024-09-301,651,200USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-231,551USD273
2024-01-01 to 2024-09-30-154,962USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-34,193,682USD
At 2024-12-31-32,259,946USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-3047,539,384shares92
2025-01-01 to 2025-09-3047,062,186shares273
2024-07-01 to 2024-09-3045,613,912shares92
2024-01-01 to 2024-09-3044,840,556shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.01USD/shares92
2025-01-01 to 2025-09-30-0.04USD/shares273
2024-07-01 to 2024-09-30-0.01USD/shares92
2024-01-01 to 2024-09-30-0.04USD/shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-09-30347,022USD
At 2024-12-31177,022USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-3062,459USD273
2024-01-01 to 2024-09-3027,078USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-540,142USD92
2025-01-01 to 2025-09-30-1,937,311USD273
2024-07-01 to 2024-09-30-577,373USD92
2024-01-01 to 2024-09-30-1,828,601USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-301,462,653USD
At 2024-12-31841,546USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-301,256,486USD
At 2024-12-31578,451USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-30491,659USD
At 2024-12-31219,190USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-09-30652,252USD
At 2024-12-31248,205USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,165,517USD92
2025-01-01 to 2025-09-303,466,898USD273
2024-07-01 to 2024-09-30847,820USD92
2024-01-01 to 2024-09-302,582,472USD274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-09-30201,627USD
At 2024-12-31150,442USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30625,375USD92
2025-01-01 to 2025-09-301,529,587USD273
2024-07-01 to 2024-09-30270,447USD92
2024-01-01 to 2024-09-30753,871USD274

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,165,517USD92
2025-01-01 to 2025-09-303,466,898USD273
2024-07-01 to 2024-09-30847,820USD92
2024-01-01 to 2024-09-302,582,472USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-3047,881,121shares
At 2024-12-3146,816,114shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-30500,000USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-3033,769,288USD
At 2024-12-3132,768,976USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-09-30117,962USD
At 2024-12-31170,940USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-09-30114,692USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2025-09-30841,414USD
At 2024-12-31609,863USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-09-30494,392USD
At 2024-12-31432,841USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-09-30390,892USD
At 2024-12-31292,400USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-3093,977USD
At 2024-12-31159,185USD

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-07-01 to 2025-09-3023,148USD92
2025-01-01 to 2025-09-3061,551USD273
2024-07-01 to 2024-09-303,972USD92
2024-01-01 to 2024-09-3011,506USD274

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,814USD92
2025-01-01 to 2025-09-303,608USD273
2024-07-01 to 2024-09-300USD92
2024-01-01 to 2024-09-301,350USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-07-01 to 2025-09-302,223USD92
2025-01-01 to 2025-09-303,575USD273
2024-07-01 to 2024-09-30-794USD92
2024-01-01 to 2024-09-301,562USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-09-303,525USD273
2024-01-01 to 2024-09-303,162USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-09-30791,418USD273
2024-01-01 to 2024-09-301,500,000USD274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30445,448USD273
2024-01-01 to 2024-09-3096,008USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-3060,304USD273
2024-01-01 to 2024-09-30-11,818USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30272,469USD273
2024-01-01 to 2024-09-30-9,101USD274

Inspect the source

Entity
Nuo Therapeutics, Inc. / CIK 0001091596
Captured
2026-09-20T05:21:57.848Z
SEC response SHA-256
f9d1094a0912aec87dd50c0e6f3c9b7f90d3de5f7435cbf00ae5d71aa22d4723

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001091596.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))